Early HCV Study Outcome: PSI-7977
Share
Follow Us
The Editors at Hepatitis Central
April 19, 2010
Learn about the mid-trial results of PSI-7977’s effectiveness against Hepatitis C.
Pharmasset jumps on hepatitis C study results
PRINCETON, N.J.
Pharmasset Inc. on Thursday reported promising early results from a clinical trial of a hepatitis C drug candidate.
The company is testing a drug candidate called PSI-7977. In the midstage trial, a group of 63 hepatitis C patients are being treated with a combination of PSI-7977 and two older drugs, Pegasys and Copegus, or Pegasys and Copegus alone. None of the patients have received any previous treatment for the disease.
Continue reading this entire article:
http://www.businessweek.com/ap/financialnews/D9F3JTC00.htm
